

# 食道癌診療指引

## 一、參與討論同仁

主席	邱仲峯院長	彭汪嘉康院士
台北癌症中心	趙祖怡副院長 (血液腫瘤科)	曾慧恩主任 (血液腫瘤科)
附設醫院	蕭世欣副主任 (胸腔內科)	吳維喬醫師 (胸腔外科)
	許思婷個管師 (癌症中心)	
萬芳醫院	張彥俊醫師 (胸腔外科)	蕭舒元個管師 (癌症中心)
雙和醫院	郭光泰主任 (胸腔外科)	王緯婷個管師 (癌症中心)


二、討論日期：108 年 11 月 06 日

三、校稿人員：郭光泰主任 / 王緯婷個管師

## 108 年版與上一版差異：

107 年版	108 年修訂版
臨床檢查 肺功能檢查 心臟功能評估	修訂 肺功能檢查 (需積極治療者) 心臟功能評估 (需積極治療者)

# 《 食道癌診療指引共識 -1 》



註：臨床高復發風險：1. Adenocarcinoma; 2. 淋巴結轉移; 3. 手術邊緣 <1mm; 4. 血管淋巴侵犯; 5. 神經侵犯

## 臨床檢查

### 必要檢查

- 病史及理學檢查
- 上消化道內視鏡
- 全血球計數
- 凝血功能測試
- 生化檢查
- 胸部斷層掃描 (掃描到上腹腔含肝臟)
- 肺功能檢查 (需積極治療者)
- 心臟功能評估 (需積極治療者)
- 營養狀況評估
- 支氣管鏡檢 (上段: 必要性, 中、下段: 選擇性)
- 胸部放射線檢查

### 選擇性檢查

- 食道鋇劑攝影
- 內視鏡超音波
- 正子掃描
- 骨頭掃描
- 腦部核磁共振

## 臨床診斷

T4, N0-2  
T1-4, N3

T any, N any  
M1

## 主要治療

1. 同步化學及放射治療
2. 化學治療
3. 放射治療
4. 支持性照護
5. 臨床試驗

同步化學及放射治療或放射治療或化學治療或臨床試驗

支持性照護

## 《參考文獻》

1. INCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers Version 2.2019.
2. AJCC Cancer Staging Manual 8th ed. 2017. p185-202. Springer International Publishing , MI:AJCC.
3. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. *Cancer Epidemiol Biomarkers Prev* 2016;25:16-27.
4. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. *Int J Epidemiol* 2001;30:1415- 1425.
5. Zhao JK, Wu M, Kim CH, et al. Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China. *Eur J Cancer Prev* 2017;26:357-364.
6. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. *Ann Thorac Surg* 2003;76:S1367-1369.
7. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2018: oesophagus cancer fact sheet. 2018.
8. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87-108.
9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019;69:7-34.\
10. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2018: United States of America cancer fact sheet. 2018.

## 《食道癌抗癌藥物治療指引》

### Preoperative Chemoradiation Therapy of Esophageal Cancer PREFERRED REGIMENS

#### Paclitaxel + Carboplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	50	1	QW	5	1
Carboplatin	AUC 2	1	QW	5	

#### Cisplatin + Fluoropyrimidine

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q4W	2(RT) + 2	2
5-FU	1000*	1-4	Q4W	2(RT) + 2	

\* Continuous infusion for 24 hours

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	15	1-5	Q3W	2	5
5-FU	800	1-5	Q3W	2	

\* Continuous infusion for 24 hours

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	30	1	QW	5	45
Capecitabine	800 PO BID	1-5	QW	5	

### Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	3(RT) + 3	5
Leucovorin	400	1	Q2W	3(RT) + 3	
5-FU	400	1	Q2W	3(RT) + 3	
5-FU	800*	1-2	Q2W	3(RT) + 3	

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1, 15, 29		For 3 doses	44
Capecitabine	625 PO BID	1-5	QW	5	

### OTHER REGIMENS

#### Cisplatin + Fluorouracil

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	100	1, 29	Q35D	1	4
5-Fu	1000	1-4, 29-32	Q35D	1	

### Irinotecan + Cisplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Irinotecan	65	1, 8, 22, 29		1	6
Cisplatin	30	1, 8, 22, 29		1	

### Paclitaxel + Fluoropyrimidine

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	45	1	QW	5	7
5-FU	300*	1-5	QW	5	

\* Continuous infusion for 24 hours

## Perioperative Chemotherapy (Include EGJ)

### PREFERRED REGIMENS

#### ECF modications

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W	6*	9
Cisplatin	60	1	Q3W	6*	
Capecitabine	625 PO BID	1-21	Q3W	6*	

\*3(pre-op) + 3(post-op)



藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W	6*	9
Oxaliplatin	130	1	Q3W	6*	
Capecitabine	625 PO BID	1-21	Q3W	6*	

\*3(pre-op) + 3(post-op)

**Oxaliplatin + Fluoropyrimidine**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	6#	22
Leucovorin	400	1	Q2W	6#	
5-FU	400	1	Q2W	6#	
5-FU	1200*	1-2	Q2W	6#	

\* Continuous infusion for 24 hours #3 (pre-op) + 3 (post-op)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	6#	19
Leucovorin	200	1	Q2W	6#	
5-FU	2600*	1	Q2W	6#	

\* Continuous infusion for 24 hours #3 (pre-op) + 3 (post-op)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W	6#	23
Capecitabine	1000 PO BID	1-14	Q3W	6#	

#3 (pre-op) + 3 (post-op)

### Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	50	1	Q2W	8 <sup>#</sup>	8
Oxaliplatin	85	1	Q2W	8 <sup>#</sup>	
Leucovorin	200	1	Q2W	8 <sup>#</sup>	
5-FU	2600*	1	Q2W	8 <sup>#</sup>	

\* Continuous infusion for 24 hours <sup>#</sup>4 (pre-op) + 4 (post-op)

### OTHER REGIMENS

#### Cisplatin + Fluorouracil

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q4W	6 <sup>#</sup>	9
5-Fu	800*	1-5	Q4W	6 <sup>#</sup>	

\* Continuous infusion for 24 hours <sup>#</sup>2-3 (pre-op) + 3-4 (post-op)

## Preoperative Chemotherapy

(Only for adenocarcinoma of the thoracic esophagus or EGJ)

### Cisplatin + Fluorouracil

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W	2 <sup>#</sup>	10
5-Fu	1000*	1-4	Q3W	2 <sup>#</sup>	

\* Continuous infusion for 24 hours <sup>#</sup>2(pre-op)

## Definitive Chemoradiation (Non-Surgical)

### PREFERRED REGIMENS

### Cisplatin + Fluoropyrimidine

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q4W	2~4 <sup>#</sup>	11
5-FU	1000*	1-4	Q4W	2~4 <sup>#</sup>	

\* Continuous infusion for 24 hours <sup>#</sup>2 (RT) + 2

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	30	1	QW	5	43
Capecitabine	800 PO BID	1-5	QW	5	

### Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	6 <sup>#</sup>	5
Leucovorin	400	1	Q2W	6 <sup>#</sup>	
5-FU	400	1	Q2W	6 <sup>#</sup>	
5-FU	800*	1-2	Q2W	6 <sup>#</sup>	

\* Continuous infusion for 24 hours #3 (RT) + 3 (post-RT)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1, 15, 29		For 3 doses	44
Capecitabine	625 PO BID	1-5	QW	5	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1, 15, 29			3
5-FU	180	1-33			

### Paclitaxel + Carboplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	50	1	QW	5	1
Carboplatin	AUC 2	1	QW	5	

**OTHER REGIMENS****Taxane + Cisplatin**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	60	1, 8, 15, 22		1	12
Cisplatin	75	1		1	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	60	1, 22		1	13
Cisplatin	80	1, 22		1	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	30	1	QW	5	14
Cisplatin	30	1	QW	5	

**Irinotecan + Cisplatin**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Irinotecan	65	1, 8, 22, 29		1	6
Cisplatin	30	1, 8, 22, 29		1	

**Paclitaxel + Fluoropyrimidine**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	45-50	1	QW	5	7
5-FU	300*	1-5	QW	5	

\* Continuous infusion for 24 hours

## Postoperative Chemoradiation (Including EGJ)

### 5-FU (bolus) + Leucovorin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Leucovorin	20	1-5	Q4W	1st, 3rd, 4th #	15, 46
5-FU	425	1-5	Q4W	1st, 3rd, 4th #	
Leucovorin	20	1-4, 31-33	Q5W	2nd (with RT)	
5-FU	400	1-4, 31-33	Q5W	2nd (with RT)	

#Cycle 1<sup>st</sup> (pre-RT), and cycle 3<sup>rd</sup>, 4<sup>th</sup> (post-RT)

### 5-FU + Leucovorin modifications

#### 1 cycle before + 2 cycle after chemoradiation

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Capecitabine	1000 PO BID	1-14	Q4W	1 + 2	47

#### 2 cycle before + 4 cycle after chemoradiation

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Leucovorin	400	1	Q2W	2 + 4	
5-FU	400	1	Q2W	2 + 4	
5-FU	1200*	1-2	Q2W	2 + 4	

\*Continuous infusion for 24 hours

**With radiation**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
5-FU	200*	1-5 or 1-7	QW	5 with RT	48

\* Continuous infusion for 24 hours

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Capecitabine	825 PO BID	1-5 or 1-7	QW	5 with RT	49

**Postoperative Chemotherapy**
**Oxaliplatin + Capecitabine**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W		16
Capecitabine	1000 PO BID	1-14	Q3W		

## Systemic therapy for metastatic or locally advanced cancer (where local therapy is not indicated)

### FIRST-LINE THERAPY

#### Trastuzumab (with chemotherapy)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Trastuzumab	8 → 6 mg/kg	1	Q3W		17

#### Trastuzumab (with chemotherapy)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Trastuzumab	6 → 4 mg/kg	1	Q2W		17

### PREFERRED REGIMENS

#### Fluoropyrimidine + Cisplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q4W		18
5-FU	1000*	1-4	Q4W		

\* Continuous infusion for 24 hours



藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1	Q2W		19, 20
Leucovorin	200	1	Q2W		
5-FU	2000*	1	Q2W		

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W		21
Capecitabine	1000 PO BID	1-4	Q3W		

**Fluoropyrimidine + Oxaliplatin**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W		22
Leucovorin	400	1	Q2W		
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W		19
Leucovorin	200	1	Q2W		
5-FU	2600*	1	Q2W		

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W		23
Capecitabine	1000 PO BID	1-14	Q3W		

## OTHER REGIMENS

### Paclitaxel + Cisplatin/Carboplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	200	1	Q3W		24
Cisplatin	75	2	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	90	1	Q2W		25
Cisplatin	50	1	Q2W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	200	1	Q3W		26
Carboplatin	AUC 5	1	Q3W		

### Docetaxel + Cisplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	75-85	1	Q3W		27, 28
Cisplatin	70-75	1	Q3W		

**Fluoropyrimidine**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Leucovorin	400	1	Q2W		20
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
5-FU	800*	1-5	Q4W		29

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	1-14	Q3W		30

**Taxane**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	100	1	Q3W		31, 32

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	250	1	Q3W		33

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	80	1	QW		34

**Irinotecan + 5-FU (only for adenocarcinoma)**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Irinotecan	180	1	Q2W		35
Leucovorin	400	1	Q2W		
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Irinotecan	80	1	QW	6 + 2(off)#	50
Leucovorin	500	1	QW	6 + 2(off)#	
5-FU	2000*	1	QW	6 + 2(off)#	

\* Continuous infusion for 24 hours #6 weeks treatment, followed by 2 weeks off

**ECF**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W		39
Cisplatin	60	1	Q3W		
5-Fu	200*	1-21	Q3W		

\* Continuous infusion for 24 hours

**ECF modifications**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W		40, 41
Oxaliplatin	130	1	Q3W		
5-Fu	200*	1-21	Q3W		

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W		40, 41
Cisplatin	60	1	Q3W		
Capecitabine	625 PO BID	1-21	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Epirubicin	50	1	Q3W		39
Oxaliplatin	130	1	Q3W		
Capecitabine	625 PO BID	1-21	Q3W		

**DCF modifications**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	40	1	Q2W		36
Leucovorin	400	1	Q2W		
5-FU	400	1	Q2W		
5-FU	1000*	1-2	Q2W		
Cisplatin	40	3	Q2W		

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	50	1	Q2W		37
Oxaliplatin	85	1	Q2W		
5-FU	1200*	1-2	Q2W		

\* Continuous infusion for 24 hours

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	75	1	Q3W		38
Carboplatin	AUC 6	2	Q3W		
5-FU	1200*	1-2	Q3W		

\* Continuous infusion for 24 hours

\*三院有個別版本

## 參考文獻

1. Van Hagen P, Hulshof MC, van Lanschot, J.J, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med 2012;366:2074-2084.
2. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-314.
3. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002;20:2844-2850.
4. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil,

- radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086-1092.
5. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCO 9102. *J Clin Oncol* 2007; 25:1160-1168.
  6. Sharma R, Yang GY, Nava HR, et al. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract]. *J Clin Oncol* 2009;27 (Suppl 15):Abstract e15619.
  7. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958.
  8. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol* 2016;17:1697-1708.
  9. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCO multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721.
  10. Alderson D, Langley RE, Nankivell MG, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072) [abstract]. *J Clin Oncol* 2015;33 (15\_suppl):Abstract 4002.
  11. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20:1167-1174.
  12. Urba SG, Orringer MB, Iannettoni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. *Cancer* 2003;98:2177-2183.
  13. Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. *Dis Esophagus* 2010;23:253-259.

14. Day FL, Leong T, Ngan S, et al. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. *Br J Cancer* 2011;104:265-271.
15. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012;30:2327-2333
16. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. *Lancet Oncol* 2014; 15:1389-1396.
17. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.
18. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009;20:1667-1673.
19. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442.
20. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. *J Clin Oncol* 2004;22:4319-4328.
21. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009;20:666-673.
22. Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract].



- J Clin Oncol 2010;28 (Suppl 15):Abstract 4006.
23. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
  24. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316-323.
  25. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. *Br J Cancer* 1998;78:511-514.
  26. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37-41.
  27. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667.
  28. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36.
  29. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54-59.
  30. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344-1347.
  31. Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 2007;24:407-412.
  32. Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014;15:78-86.
  33. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086-1091.

34. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 2007;18:898-902.
35. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en ncologie) Study. *J Clin Oncol* 2014;32:3520-3526.
36. Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. *J Clin Oncol* 2015;33:3874-3879.
37. Shankaran V, Mulcahy MF, Hochster HS, et al. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: Preliminary results of a phase II study. *Gastrointestinal Cancers Symposium 2009:Abstract 47*.
38. Elkerm YM, Elsaid A, AL-Batran S, Pauligk C. Final results of a phase II trial of docetaxel-carboplatin-FU in locally advanced gastric carcinoma [abstract]. Presented at the Gastrointestinal Cancers Symposium 2008. Abstract 38.
39. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol* 2002;20:1996-2004.
40. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. *Br J Cancer* 2005;92:1976-1983.
41. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008;358:36-46.
42. NCCN. [ESOPH-F 7 of 12] esophageal and esophagogastric junction cancers: version 2, 2018.
43. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Science2017;357:409-413.

44. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200.
45. Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. *Jpn J Clin Oncol* 2007;37:829-835.
46. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.
47. Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. *Int J Radiat Oncol Biol Phys* 2007;69:1424-1428.
48. Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the trans-tasman radiation oncology group. *Int J Radiat Oncol Biol Phys* 2011;79:690-695.
49. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. *World J Gastroenterol* 2006;12:603-607.
50. Wolff K, Wein A, Reulbach U, et al. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. *Anticancer Drugs* 2009;20:165-173.

## 《 食道癌放射治療共識 》

### 一、治療範圍

1. 食道腫瘤或腫瘤原發部位
2. 淋巴轉移病灶
3. 高風險淋巴轉移範圍

### 二、治療劑量 / 次數

#### ▲輔助性放射治療 ( 手術後 )

##### 1. 總劑量

- (a) 殘餘腫瘤 / 腫瘤原發部位：50Gy(50~50.4Gy) \*
- (b) 高風險範圍：48Gy(45~50.4Gy)
- (c) 照射次數：27 次 (25~30 次)

#### ▲根治性放射治療 ( 無手術 )

##### 1. 總劑量

- (a) 腫瘤：50Gy(50~50.4Gy) \*
- (b) 高風險範圍：48Gy(45~50.4Gy)
- (c) 照射次數：27 次 (25~30 次)

\* 上段食道癌可考慮增加劑量至 60~66 Gy；中下段食道癌可考慮增加劑量至 60 Gy。

#### ▲前導性放射治療 ( 手術前 )

##### 1. 總劑量

- (a) 腫瘤：48Gy(45~50.4Gy)
- (b) 高風險範圍：48Gy(45~50.4Gy)
- (c) 照射次數：27 次 (25~30 次)

或是

2. 總劑量

- (a) 腫瘤：41.4Gy
- (b) 高風險範圍：41.4Gy
- (c) 照射次數：23 次

### 三、治療方式：

使用強度調控放射治療技術，包含弧形及螺旋放射規畫，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量。

### 四、參考文獻：

1. International Commission on Radiation Units and Measurements. ICRU Report No 50: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: ICRU Publications 1993.
2. Cooper JS, GUO MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01) . Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
3. International Commission on Radiation Units and Measurements. ICRU Report No 62: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: ICRU Publications 1999.
4. Shi XH, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 1999; 51: 21-26.
5. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
6. Willett CG, et al. Principles and Practice of Radiation Oncology. 5th edition: Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1131-1153.
7. P. van Hagen, M.C.C.M. Hulshof, J.J.B. van Lanschot, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med 2012; 366:2074-2084.
8. NCCN clinical practice guidelines in oncology for esophageal and esophagogastric junction cancers. Version 3, 2019.

